Everest Medicines announced a $224 million partnership with San Diego’s Arena Pharma to develop two Arena small molecule candidates in China and southeast Asia. Both candidates are in US clinical trials. Ralinepag is aimed at pulmonary arterial hypertension, and etrasimod is being tested in autoimmune diseases. Everest is a new company, dedicated to bringing innovative western drugs to China and backed with $50 million in an initial financing led by China’s C-Bridge Capital. C-Bridge describes Everest as its incubator platform for bringing novel drugs to China.
Source: China Biotoday
